As we conclude the third year of Vynamic’s Sustainability Council, we have the opportunity to reflect on our progress in driving our strategies forward. We are excited to continue making intentional steps towards our sustainability ambitions, encourage our employees to consider their carbon contribution, and actively support our local communities with impactful initiatives. We look forward to continuing to develop our role supporting clients to achieve their sustainability ambitions, recognizing that sustainability is a non-negotiable for the health industry as we aspire to foster a healthier world.
We’re proud to present our third annual Sustainability report, which details our team’s strategic efforts, activities, and community engagements throughout 2024, and offers a look ahead to our goals for 2025.
Vynamic, an Inizio Advisory company, is a leading management consulting partner to global health organizations across Life Sciences, Health Services, and Health Technology. Founded and headquartered in Philadelphia, Vynamic has offices in Boston, Durham NC, New York, and London. Our purpose is simple: We believe there is a better way. We are passionate about shaping the future of health, and for more than 20 years we’ve helped clients transform by connecting strategy to action.
Through a structured, yet flexible delivery model, our accomplished leaders work as an extension of client teams, enabling growth, performance, and culture. Vynamic has been recognized by organizations like Great Place to Work and Business Culture Awards for being leaders and innovators in consulting, company culture, and health. Visit Vynamic.com to discover how we can help transform your
organization or your career.
Jump to a slide with the slide dots.
Learn how to optimize AI-powered omnichannel strategies for better engagement, data governance, and measurable results in life sciences
Read moreDiscover how healthcare orgs drive sustainable change through strategy, leadership, and execution—insights from Vynamic leaders.
Read moreLayoffs at U.S. health agencies, IRA, and budget cuts disrupt pharma—learn how life sciences can adapt and stay resilient.
Read more